/
Oncology
Acute Myeloid Leukemia (AML)
34
Pipeline Programs↗
23
Active Trials↗
25
Companies Involved↗
Acute Myeloid Leukemia (AML) is a moderately active landscape with 34 programs across 25 companies. The most active players are Eli Lilly. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 19
Phase 24
Phase 310
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
30 of 31 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 91% of 34 pipeline programs.
Analysis
Trial Status
26
clinical trials
Recruiting12 · 46%
Not yet recruiting7 · 27%
Active, not recruiting3 · 12%
Completed2 · 8%
Terminated1 · 4%
Enrolling by invitation1 · 4%
Clinical Trials
Trial Activity
26 trials
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Active, not recruiting·
Institut de Recherches Internationales Servier·Phase 3·NCT03173248·146 enrolled
Institut de Recherches Internationales Servier·Phase 3·NCT03173248·146 enrolledPage 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)